申请人:Banyu Pharmaceutical Co., Ltd.
公开号:US07960402B2
公开(公告)日:2011-06-14
A compound represented by, e.g. the formula (I):
[wherein X, Y, Z, and W each independently represent optionally substituted methine; A, B, and D each independently represent —C(O)—, etc.; Q represents a methine or a nitrogen; and R represents the formula (II-1), optionally substituted with lower alkyl, etc.;
(wherein R6 represents a lower alkyl, etc; and R7 and R8 each independently represents a lower alkyl, etc.)] or a pharmaceutically acceptable salt of the compound. The compounds and salt have antagonistic activity against a histamine H3 receptor or inverse agonistic activity against a histamine H3 receptor. They are useful in the prevention or treatment of metabolic diseases, circulatory diseases, or neurotic diseases.
化合物的化学式表示为(I),例如:[其中X、Y、Z和W各自独立地表示可选择性地取代的亚甲基;A、B和D各自独立地表示—C(O)—等;Q表示亚甲基或氮;R表示公式(II-1),可选择性地用较低的烷基等取代;(其中R6表示较低的烷基等;而R7和R8各自独立地表示较低的烷基等)]或该化合物的药学可接受盐。该化合物和盐对组胺H3受体具有拮抗活性或反向激动剂活性。它们在预防或治疗代谢性疾病、循环系统疾病或神经疾病方面非常有用。